- Q1 2024 Cardiff Oncology Inc Earnings Call TranscriptMay 02, 2024$4.48 (+5.91%)Earnings
- Q4 2023 Cardiff Oncology Inc Earnings Call TranscriptFeb 29, 2024$1.77 (-3.02%)Earnings
- Q3 2023 Cardiff Oncology Inc Earnings Call TranscriptNov 02, 2023$1.14 (+8.57%)Earnings
- Cardiff Oncology Inc Clinical Update Call TranscriptSep 26, 2023
- Cardiff Oncology Inc Clinical and Corporate Update Call TranscriptAug 07, 2023
- Cardiff Oncology Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Cardiff Oncology Inc at Cowen Health Care Conference- GI/GU Oncology Panel TranscriptMar 07, 2023
- Cardiff Oncology Inc at JMP Securities Hematology Oncology Summit (Virtual) TranscriptDec 07, 2022
- Cardiff Oncology Inc at Piper Sandler Healthcare Conference TranscriptNov 29, 2022
- Cardiff Oncology Inc to Provide a Clinical and Corporate Update Call TranscriptSep 12, 2022
- Cardiff Oncology Inc to Discuss Updated Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer at ASCO-GI TranscriptJan 18, 2022
- Cardiff Oncology Inc to Discuss New Data from Lead Clinical Program in KRAS-mutated mCRC Webinar TranscriptSep 08, 2021
- Cardiff Oncology Inc at William Blair Biotech Focus Conference (Virtual) TranscriptJul 15, 2021
- Cardiff Oncology Inc KOL Webinar TranscriptApr 12, 2021
- Cardiff Oncology Inc Discusses KRAS Mutations in Cancer TranscriptOct 14, 2020
- Cardiff Oncology, Inc. - Special Call TranscriptSep 23, 2020
- Cardiff Oncology Inc Onvansertib Clinical Trials TranscriptMay 18, 2020
- Trovagene Inc at Needham Healthcare Conference TranscriptApr 15, 2020
- Trovagene Inc Business Update Conference Call TranscriptJun 07, 2019
Cardiff Oncology Inc at Cowen Health Care Conference- GI/GU Oncology Panel Transcript
Panel is the GI/GU Oncology Panel. And with us we have six companies. I'm just going to introduce them one by one in alphabetical order. We have Daniel O'Connor from Ambrx; we have Mark Erlander from Cardiff; we have Joe Ferra from Elevation Oncology; we have Scott Koenig from MacroGenics; Joe McCann from POINT Biopharma; and Liz Barrett from UroGen. I thank everybody for joining us.
Questions & Answers
In terms of the format, we're going to ask only two general questions to the panelists. And then we're going to go round with specific company focused questions. So first question is in GI/GU Oncology includes obviously a wide range of tumor types, each of which has unique development considerations. However, there are some regulatory factors that broadly apply to all these tumors. And I'll start with project documents. Are you incorporating that in your clinical development?
So maybe let's just start with, I guess the left side of the table (multiple speakers).
'
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)